-- Oral presentation to highlight Phase 2a
Part A results of the randomized, placebo-controlled SIGNAL-AA
clinical trial evaluating bempikibart in patients with severe and
very severe alopecia areata (AA) --
WALTHAM,
Mass., Feb. 28, 2025 /PRNewswire/ -- Q32 Bio
Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology
company focused on developing biologic therapeutics to restore
immune homeostasis, today announced that results from Part A of its
SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with
alopecia areata (AA) will be presented in a late-breaking oral
session at the 2025 American Academy of Dermatology (AAD) Annual
Meeting, taking place March 7-11 in
Orlando, FL. Bempikibart is a
fully human anti-IL-7Rα antibody that re-regulates adaptive immune
function by blocking IL-7 and TSLP signaling for the treatment of
AA currently being evaluated in a Phase 2 program.
"We are honored that the Phase 2a SIGNAL-AA data from
bempikibart was selected for an oral late-breaking presentation at
this year's AAD annual meeting, which provides recognition of its
promising clinical activity and well-tolerated safety profile. This
acknowledgement reinforces our conviction in bempikibart's
potential to transform the treatment paradigm for a disease in
desperate need of better options," said Jodie Morrison, Chief Executive Officer of Q32
Bio. "The growing enthusiasm in the field underscores our decision
to focus on advancing bempikibart in AA, and we look forward to
sharing our results."
Oral Presentation Details:
Title: Initial Results from the SIGNAL-AA Study:
Randomized Placebo Controlled Phase 2a Trial of a Bempikibart,
Novel IL-7/TSLP Bifunctional Receptor Antagonist in Patients with
Severe or Very Severe Alopecia Areata
Presenter: Brett King, M.D.,
Ph.D., of Dermatology Physicians of Connecticut, and former Associate Professor of
Dermatology, Yale University School of
Medicine
Session Title: S028 - Late-Breaking Research: Session 1
Date & Time: Saturday, March 8,
2025, from 10:36 a.m. to 10:48
a.m. ET
Location: Chapin Theater – Level II
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science
targets potent regulators of the adaptive immune system to
re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human
anti-IL-7Rα antibody that re-regulates adaptive immune function for
the treatment of autoimmune diseases being evaluated in a Phase 2
program. The IL-7 and TSLP pathways have been genetically and
biologically implicated in driving several T cell-mediated
pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our
investors and the public using our company
website www.Q32Bio.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference
call transcripts and webcast transcripts, as well as on X (formerly
Twitter) and LinkedIn. The information that we post on our website
or on X or LinkedIn could be deemed to be material information. As
a result, we encourage investors, the media and others interested
to review the information that we post there on a regular basis.
The contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Forward-Looking Statements
This communication contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995, as amended, and other federal securities laws. Any
statements contained herein which do not describe historical facts,
including, among others, our beliefs, observations, expectations
and assumptions regarding the topline data from the SIGNAL-AA Phase
2a and the safety, tolerability, clinical activity, potential
efficacy and potential benefits of bempikibart; which involve risks
and uncertainties that could cause actual results to differ
materially from those discussed in such forward-looking
statements.
Forward-looking statements are based on management's current
beliefs and assumptions, which are subject to risks and
uncertainties and are not guarantees of future
performance. Such risks and uncertainties include, among
others, the risk that additional data, or the results of ongoing
data analyses, may not support our current beliefs and expectations
for bempikibart, future clinical studies, including that Part B of
the SIGNAL-AA Phase 2a clinical trial, may not be completed by the
first half of 2026 or at all, might be more costly than expected or
might not yield anticipated results, and such other risks and
uncertainties identified in the Company's periodic, current and
other filings with the U.S. Securities and Exchange Commission,
including its Quarterly Report on Form 10-Q for the quarter ended
September 30, 2024 and any subsequent
filings with the Commission, which are available at the SEC's
website at www.sec.gov. Any such risks and uncertainties could
materially and adversely affect the Company's results of operations
and its cash flows, which would, in turn, have a significant and
adverse impact on the Company's stock price. We caution you
not to place undue reliance on any forward-looking statements,
which speak only as of the date they are made. The Company
disclaims any obligation to publicly update or revise any such
statements to reflect any change in expectations or in events,
conditions or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking
statements.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-announces-late-breaking-presentation-of-results-from-signal-aa-part-a-clinical-trial-of-bempikibart-in-alopecia-areata-at-the-2025-american-academy-of-dermatology-annual-meeting-302388185.html
SOURCE Q32 Bio
